Meeting
2024 ASCO Genitourinary Cancers Symposium
Health-related quality of life (HRQoL) profile and clinical outcomes in first-line (1L) advanced renal cell carcinoma (aRCC): A modelling analysis based on CheckMate 9ER (CM9ER) trial.
Authors
Jens Bedke
Eberhard Karls Universität Tübingen, Tübingen, Germany
Jens Bedke , Rachel H. Giles , Thomas Powles , Michael Derosa , Lysbeth Floden , Intan Purnajo , Mickael Lothgren , Alessia Ogareva , David Cella
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Clinical Trial Registration Number
NEED TRIAL NUMBER
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 384)
DOI
10.1200/JCO.2024.42.4_suppl.384
Abstract #
384
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.
First Author: David Cella
Poster
2023 ASCO Annual Meeting
Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.
First Author: David Cella
Poster
2023 ASCO Genitourinary Cancers Symposium
CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.
First Author: Philippe Barthelemy
Poster
2022 ASCO Genitourinary Cancers Symposium
Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
First Author: Thomas Powles